Business
Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017
Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO Internatio...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\nResverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nCALGARY, June 5, 2017\n\n\n\nCALGARY, June 5, 2017 /CNW/ - Resverlogix Corp. (\"Resverlogix\" or the \"Company\") (TSX:RVX) is pleased to announce that a recently submitted paper titled: \"Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)\" was published in the Journal of Cardiovascular Translational Research. The Company also provided details of its upcoming participation in an upcoming industry conference.\n\nApabetalone Published In Journal of Cardiovascular Translational Research\n\nThis publication discusses how through transcriptional regulation, apabetalone modulates pathways that underlie cardiovascular disease (CVD) including reverse cholesterol transport, vascular inflammation, coagulation, and complement a pathway which includes many CVD risk factors that are dysregulated. Using advanced technologies such as transcriptomics and proteomics the data clearly illustrated that complement is one of the pathways most downregulated by apabetalone in cells and in plasma from CVD patients previously treated with apabetalone. Plasma proteomics of CVD patients shows that apabetalone significantly decreases complement proteins and regulators indicating decreased activity of complement in patients. As complement components are linked to CVD and metabolic syndrome, including major acute cardiac events, modulating their levels and activity by apabetalone may alleviate risks associated with these diseases.\n\nCommenting on the recent publication, Mr. Donald McCaffrey, President and Chief Executive Officer stated, \"This is but one of several papers we will publish this year in the field of BET inhibition and epigenetics. I am extremely pleased that our science team continues to demonstrate leadership in the field of BET inhibition and the potential for apabetalone to reduce risks associated with CVD rela...